GlassScriptPhysician profile
Naveen T Lobo
NPI 1023025434
$5,924.24
in general payments reported to CMS, 2019-2025
52 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $436 · 2021: $77.21 · 2022: $105 · 2023: $674 · 2024: $1,005 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Education: $137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.56 |
| Education | $137.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $466.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $459.44 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $423.45 | 2019-2025 | Opdivo, Krazati |
| Novartis Pharmaceuticals Corporation | $329.77 | 2019-2025 | |
| Amgen INC. | $287.89 | 2019-2023 | Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $282.34 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $271.85 | 2019-2025 | |
| Janssen Biotech, INC. | $271.31 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Seagen INC. | $264.21 | 2019-2023 | Tukysa, Padcev, Tivdak |
| Merck Sharp & Dohme LLC | $254.17 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $217.44 | 2019-2025 | Enhertu, Datroway |
| Genzyme Corporation | $186.12 | 2019-2025 | |
| Gilead Sciences, INC. | $179.05 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $164.93 | 2024-2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $134.94 | 2019-2025 | Jaypirca, Verzenio |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Lobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.